BACKGROUND: The active metabolite of vitamin D 1α,25-dihydroxycholecalciferol (1,25D(3) ) has exhibited broad-spectrum antitumor activity in xenograft animal models. However, its activity against metastatic disease has not been extensively investigated. METHODS: Squamous cell carcinoma (SCC) or 1,25D(3) -resistant variant SCC-DR cells were treated with 1,25D(3) . Actin organization was examined by immunofluorescence assay. Cell migration was assessed by "wound" healing and chemotactic migration assays. Cell invasion was assessed by a Matrigel-based invasion assay and in situ zymography. Matrix metalloproteinase 2 (MMP-2) and MMP-9 expression and secretion were examined by immunoblot analysis and an enzyme-linked immunosorbent assay, respectively. E-cadherin expression was assessed by flow cytometry, immunoblot analysis, and immunohistochemistry. Knockdown of E-cadherin was achieved by small interfering RNA. An experimental metastasis mouse model was created by intravenous injection of tumor cells; and lung tumor development in the mice was assessed by magnetic resonance imaging, gross observation, and histology. RESULTS: SCC cellular morphology and actin organization were altered by 10 nM 1,25D(3) . 1,25D(3) inhibited SCC cell motility and invasion, which were associated with reduced expression and secretion of MMP-2 and MMP-9, and 1,25D(3) promoted the expression of E-cadherin. These findings were not observed in SCC-DR cells. Knock down of E-cadherin rescued 1,25D(3) -inhibited cell migration. Intravenous injection of SCC or SCC-DR cells resulted in the establishment of extensive pulmonary lesions in saline-treated C3H mice. Treatment with 1,25D(3) resulted in a marked reduction in the formation of lung tumor colonies in mice that were injected with SCC cells, but not in mice that were injected with SCC-DR cells. CONCLUSIONS: 1,25D(3) suppressed SCC cell motility, invasion, and metastasis, partially through the promotion of E-cadherin-mediated cell-cell adhesion.
BACKGROUND: The active metabolite of vitamin D 1α,25-dihydroxycholecalciferol (1,25D(3) ) has exhibited broad-spectrum antitumor activity in xenograft animal models. However, its activity against metastatic disease has not been extensively investigated. METHODS:Squamous cell carcinoma (SCC) or 1,25D(3) -resistant variant SCC-DR cells were treated with 1,25D(3) . Actin organization was examined by immunofluorescence assay. Cell migration was assessed by "wound" healing and chemotactic migration assays. Cell invasion was assessed by a Matrigel-based invasion assay and in situ zymography. Matrix metalloproteinase 2 (MMP-2) and MMP-9 expression and secretion were examined by immunoblot analysis and an enzyme-linked immunosorbent assay, respectively. E-cadherin expression was assessed by flow cytometry, immunoblot analysis, and immunohistochemistry. Knockdown of E-cadherin was achieved by small interfering RNA. An experimental metastasis mouse model was created by intravenous injection of tumor cells; and lung tumor development in the mice was assessed by magnetic resonance imaging, gross observation, and histology. RESULTS:SCC cellular morphology and actin organization were altered by 10 nM 1,25D(3) . 1,25D(3) inhibited SCC cell motility and invasion, which were associated with reduced expression and secretion of MMP-2 and MMP-9, and 1,25D(3) promoted the expression of E-cadherin. These findings were not observed in SCC-DR cells. Knock down of E-cadherin rescued 1,25D(3) -inhibited cell migration. Intravenous injection of SCC or SCC-DR cells resulted in the establishment of extensive pulmonary lesions in saline-treated C3H mice. Treatment with 1,25D(3) resulted in a marked reduction in the formation of lung tumor colonies in mice that were injected with SCC cells, but not in mice that were injected with SCC-DR cells. CONCLUSIONS: 1,25D(3) suppressed SCC cell motility, invasion, and metastasis, partially through the promotion of E-cadherin-mediated cell-cell adhesion.
Authors: M Shabahang; R R Buras; F Davoodi; L M Schumaker; R J Nauta; M R Uskokovic; R V Brenner; S R Evans Journal: Cancer Res Date: 1994-08-01 Impact factor: 12.701
Authors: Li Laine Ooi; Hong Zhou; Robert Kalak; Yu Zheng; Arthur D Conigrave; Markus J Seibel; Colin R Dunstan Journal: Cancer Res Date: 2010-02-16 Impact factor: 12.701
Authors: Li Laine Ooi; Yu Zheng; Hong Zhou; Trupti Trivedi; Arthur D Conigrave; Markus J Seibel; Colin R Dunstan Journal: Bone Date: 2010-07-16 Impact factor: 4.398
Authors: Li Ma; Jennifer Young; Harsha Prabhala; Elizabeth Pan; Pieter Mestdagh; Daniel Muth; Julie Teruya-Feldstein; Ferenc Reinhardt; Tamer T Onder; Scott Valastyan; Frank Westermann; Frank Speleman; Jo Vandesompele; Robert A Weinberg Journal: Nat Cell Biol Date: 2010-02-21 Impact factor: 28.824
Authors: Natalia Pendás-Franco; José Manuel González-Sancho; Yajaira Suárez; Oscar Aguilera; Andreas Steinmeyer; Carlos Gamallo; María T Berciano; Miguel Lafarga; Alberto Muñoz Journal: Differentiation Date: 2006-12-11 Impact factor: 3.880
Authors: Yingyu Ma; Wei-Dong Yu; Pamela A Hershberger; Geraldine Flynn; Rui-Xian Kong; Donald L Trump; Candace S Johnson Journal: Mol Cancer Ther Date: 2008-09 Impact factor: 6.261
Authors: Adrianna Mostowska; Stefan Sajdak; Piotr Pawlik; Margarita Lianeri; Paweł P Jagodzinski Journal: Oncol Lett Date: 2015-12-15 Impact factor: 2.967